$94.230
+1.234 (+1.31%)收盘时
MDT 资讯
MDT 事件
Medtronic Shares Up 0.51% to $92.39
Moderately bullish activity in Medtronic (MDT), with shares up 46c, or 0.51%, near $92.39. Options volume relatively light with 30k contracts traded and calls leading puts for a put/call ratio of 0.69, compared to a typical level near 0.86. Implied volatility (IV30) is higher by 0.1 points near 26.16,and above the 52wk median, suggesting an expected daily move of $1.52. Put-call skew flattened, suggesting a modestly bullish tone.
Notable Stock Gains for Medtronic and Others
Notable gainers among liquid option names this morning include Medtronic (MDT) $92.33 +3.84, Meta Platforms Inc (META) $746.15 +27.48, First Solar (FSLR) $184.45 +6.63, Biogen (BIIB) $232.73 +7.02, and Accenture (ACN) $215.31 +6.25.
Medtronic Announces Oversubscribed MiniMed Stock Exchange
Medtronic (MDT) announced that, based on preliminary results, its previously announced offer to exchange shares of common stock of MiniMed Group (MMED) for outstanding Medtronic ordinary shares was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on October 9. Medtronic has decided to exchange all of its remaining interest in MiniMed, totaling 252,813,348 shares of MiniMed common stock. Under the terms of the exchange offer, 4.5939 shares of MiniMed common stock will be exchanged for each Medtronic ordinary share accepted in the exchange offer.
AMA Approves New CPT Codes for Medtronic
Medtronic announced that the American Medical Association approved new Category I Current Procedural Terminology - CPT - codes for two of its technologies: Altaviva implantable tibial neuromodulation device for the treatment of urge urinary incontinence and Symplicity Spyral renal denervation system for the treatment of uncontrolled hypertension. The new codes, which will replace existing Category III codes, are effective January 2028. Category I CPT codes are permanent codes assigned to procedures the AMA has determined are well established, widely performed by physicians across the U.S., and supported by clinical evidence, in addition to other criteria identified in the application process. A Category I CPT does not determine coverage, reimbursement, clinical superiority, or patient access.
Medtronic Achieves Regulatory Milestones for Cardiac Ablation Software
Medtronic announced regulatory milestones for software used with two cardiac ablation platforms. This includes FDA clearance and CE Mark for the latest Affera Prism-2 Mapping Software. The company also obtained CE Mark for the PulseSelect ProxBox Adapter with Proximity Indicator software. These milestones expand integrated mapping and tissue-proximity capabilities across the Medtronic cardiac ablation portfolio. The Affera Prism-2 Mapping Software helps physicians create detailed three-dimensional maps of the heart's electrical activity during cardiac ablation procedures for arrhythmias, or abnormal heart rhythms. The software uses magnetic and impedance-based tracking to display the location of specialized and conventional diagnostic catheters, including coronary sinus catheters, on a three-dimensional map. This capability can support procedures that use little or no fluoroscopy, reducing reliance on X-ray imaging during cardiac ablation. The Affera Mapping and Ablation System is the platform used with the Sphere-9 Catheter, an all-in-one catheter that combines high-definition mapping with dual-energy pulsed field and radiofrequency ablation.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。